# House Research

# -Act Summary-

**Chapter:** 162 **Session:** 2018 Regular Session

**Topic:** Step therapy override

**Analyst:** Larie Ann Pampuch

(larie.pampuch@house.mn) **Date:** May 21, 2018

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

### **Overview**

This act creates a process by which an enrollee and prescribing health care provider can override a health plan company's step therapy protocol (the protocol that requires an enrollee to use a specific prescription medication before receiving a different prescription medication).

### **Section**

- 1 [62Q.184] Step therapy override.
  - **Subd. 1. Definitions.** Provides definitions.
  - **Subd. 2. Establishment of a step therapy protocol.** Requires health plan companies to use clinical practice guidelines when establishing a step therapy protocol and provide an enrollee with the applicable clinical review criteria upon request.
  - **Subd. 3. Step therapy override process; transparency.** (a) Requires that if a health plan company restricts the use of a prescription drug, they must provide a clear, readily accessible, and convenient process for health care providers and enrollees to request an override. The process must be available on the health plan company's website and a health plan company that has an existing medical exceptions process can continue to use that process. Requires a health plan company to grant an override if the prescription drug and/or enrollee meets certain conditions.
  - (b) Requires a health plan company to coverage for a prescription drug that is part of a step therapy override if the prescription drug is covered under the enrollee's health plan.
  - (c) Clarifies that an enrollee or provider can appeal the denial of an override using the complaint procedure in sections 62Q.68 to 62Q.73.

Chapter 162 May 21, 2018
Page 2

### **Section**

(d) Requires a health plan company to state why a step therapy override was not granted and provide information regarding a request for an external review of the denial under section 62Q.73. Provides that a denial that is upheld on appeal is final and is then eligible for a request for external review.

- (e) Requires a health plan company to respond for a request for an override or an appeal within 5 days, or within 72 hours if there are exigent circumstances. Provides that if a health plan company does not respond within these time limits the request is granted.
- (f) Requires step therapy override requests be accessible to health care providers and allow them to submit the request to group purchasers electronically.
- (g) Clarifies that nothing in this section prohibits a health plan company from requesting relevant medical records, requiring an enrollee to try a generic or biosimilar equivalent before covering a branded drug.
- (h) Clarifies that this section cannot be construed to allow a drug sample to serve the primary purpose of a step therapy override.

**Effective date.** This section is effective January 1, 2019, and applies to health plans after that date.